Severe bullous disorders, KELA reimbursement

L12_PEMPHIKELA

vesiculobullous skin disease: Skin diseases characterized by local or general distributions of vesicles and bullae (i.e. blisters). Both vesicles and bullae are fluid-filled lesions, distinguished by size (vesicles being less than 5–10 mm and bullae being larger than 5–10 mm). Vesiculobullous diseases are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. In the case of vesiculobullous diseases which are also immune disorders, the term immunobullous is sometimes used. (From Scientific American Medicine, 1990, and Wikipedia)

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

KELA reimbursements: KELA codes 135

Check pre-conditions, main-only, mode, ICD version None

Check minimum number of events None

Include endpoints None

L12_PEMPHIKELA

Extra metadata

Level in the ICD hierarchy 3

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Severe bullous disorders, KELA reimbursement based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	31	15	16
Unadjusted prevalence (%)	0.01	0.01	0.01
Mean age at first event (years)	58.72	57.94	59.46

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: L12_PEMPHIKELA – Severe bullous disorders, KELA reimbursement
GWS hits:

Survival analyses between endpoints

↥

Plot

before Severe bullous disorders, KELA reimbursement
after Severe bullous disorders, KELA reimbursement

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Severe bullous disorders, KELA reimbursement

↥